Definium Therapeutics, Inc. Common Shares Earnings Dividend

Definium Therapeutics, Inc. Common Shares’s revenue jumped NaN% since last year same period to $0Mn in the Q1 2026. On a quarterly growth basis, Definium Therapeutics, Inc. Common Shares has generated NaN% jump in its revenue since last 3-months.

Definium Therapeutics, Inc. Common Shares’s net profit fell -230.21% since last year same period to $-77.1Mn in the Q1 2026. On a quarterly growth basis, Definium Therapeutics, Inc. Common Shares has generated -52.86% fall in its net profits since last 3-months.

Definium Therapeutics, Inc. Common Shares’s net profit margin jumped NaN% since last year same period to -Inf% in the Q1 2026. On a quarterly growth basis, Definium Therapeutics, Inc. Common Shares has generated NaN% jump in its net profit margins since last 3-months.

Definium Therapeutics, Inc. Common Shares’s earning per share (EPS) estimates for the current quarter stand at -0.48 - a -5.93% fall from last quarter’s estimates.

Definium Therapeutics, Inc. Common Shares’s earning per share (EPS) estimates for the current year stand at -0.48.

Definium Therapeutics, Inc. Common Shares’s earning per share (EPS) fell -102.86% since last year same period to -0.71 in the Q1 2026. This indicates that the Definium Therapeutics, Inc. Common Shares has generated -102.86% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Definium Therapeutics, Inc. Common Shares’s return on assets (ROA) stands at -0.36.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Definium Therapeutics, Inc. Common Shares’s return on equity (ROE) stands at -0.95.